Emerging therapies and real-world application of metabolic dysfunction-associated steatotic liver disease treatment
Metabolic dysfunction-associated steatotic liver disease, formerly referred to as non-alcoholic fatty liver disease, is the most common liver disease in Western countries and has emerged as the leading indication for liver transplantation. Metabolic dysfunction-associated steatohepatitis (MASH), a m...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Korean Association for the Study of the Liver
2025-07-01
|
| Series: | Clinical and Molecular Hepatology |
| Subjects: | |
| Online Access: | http://e-cmh.org/upload/pdf/cmh-2025-0083.pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849415231529287680 |
|---|---|
| author | Hee Yeon Kim Mary E. Rinella |
| author_facet | Hee Yeon Kim Mary E. Rinella |
| author_sort | Hee Yeon Kim |
| collection | DOAJ |
| description | Metabolic dysfunction-associated steatotic liver disease, formerly referred to as non-alcoholic fatty liver disease, is the most common liver disease in Western countries and has emerged as the leading indication for liver transplantation. Metabolic dysfunction-associated steatohepatitis (MASH), a more advanced stage, carries a high risk of progression to liver fibrosis, cirrhosis, liver failure, and hepatocellular carcinoma. Until recently, lifestyle intervention remained the mainstay of MASH management, with no pharmacological treatments specifically approved. However, advances in understanding its pathophysiological mechanisms have fueled numerous clinical trials, culminating in the Food and Drug Administration’s (FDA) approval of resmetirom as the first treatment for MASH in 2024. Additionally, many investigational drugs are nearing FDA approval or progressing through late-stage clinical trials. This review examines the current therapeutic landscape, highlights strategies for identifying patients suitable for liver-directed therapies in real-world settings, and discusses the challenges that remain. |
| format | Article |
| id | doaj-art-8a3a112b98b94dd4a52b2ee90934c1ff |
| institution | Kabale University |
| issn | 2287-2728 2287-285X |
| language | English |
| publishDate | 2025-07-01 |
| publisher | Korean Association for the Study of the Liver |
| record_format | Article |
| series | Clinical and Molecular Hepatology |
| spelling | doaj-art-8a3a112b98b94dd4a52b2ee90934c1ff2025-08-20T03:33:35ZengKorean Association for the Study of the LiverClinical and Molecular Hepatology2287-27282287-285X2025-07-0131375377010.3350/cmh.2025.00832227Emerging therapies and real-world application of metabolic dysfunction-associated steatotic liver disease treatmentHee Yeon Kim0Mary E. Rinella1 Department of Internal Medicine, Bucheon St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea Division of Gastroenterology, Hepatology and Nutrition, University of Chicago Pritzker School of Medicine, Chicago, IL, USAMetabolic dysfunction-associated steatotic liver disease, formerly referred to as non-alcoholic fatty liver disease, is the most common liver disease in Western countries and has emerged as the leading indication for liver transplantation. Metabolic dysfunction-associated steatohepatitis (MASH), a more advanced stage, carries a high risk of progression to liver fibrosis, cirrhosis, liver failure, and hepatocellular carcinoma. Until recently, lifestyle intervention remained the mainstay of MASH management, with no pharmacological treatments specifically approved. However, advances in understanding its pathophysiological mechanisms have fueled numerous clinical trials, culminating in the Food and Drug Administration’s (FDA) approval of resmetirom as the first treatment for MASH in 2024. Additionally, many investigational drugs are nearing FDA approval or progressing through late-stage clinical trials. This review examines the current therapeutic landscape, highlights strategies for identifying patients suitable for liver-directed therapies in real-world settings, and discusses the challenges that remain.http://e-cmh.org/upload/pdf/cmh-2025-0083.pdfclinical trialsmetabolic dysfunction-associated steatotic liver diseasepharmacological treatmentssteatohepatitis |
| spellingShingle | Hee Yeon Kim Mary E. Rinella Emerging therapies and real-world application of metabolic dysfunction-associated steatotic liver disease treatment Clinical and Molecular Hepatology clinical trials metabolic dysfunction-associated steatotic liver disease pharmacological treatments steatohepatitis |
| title | Emerging therapies and real-world application of metabolic dysfunction-associated steatotic liver disease treatment |
| title_full | Emerging therapies and real-world application of metabolic dysfunction-associated steatotic liver disease treatment |
| title_fullStr | Emerging therapies and real-world application of metabolic dysfunction-associated steatotic liver disease treatment |
| title_full_unstemmed | Emerging therapies and real-world application of metabolic dysfunction-associated steatotic liver disease treatment |
| title_short | Emerging therapies and real-world application of metabolic dysfunction-associated steatotic liver disease treatment |
| title_sort | emerging therapies and real world application of metabolic dysfunction associated steatotic liver disease treatment |
| topic | clinical trials metabolic dysfunction-associated steatotic liver disease pharmacological treatments steatohepatitis |
| url | http://e-cmh.org/upload/pdf/cmh-2025-0083.pdf |
| work_keys_str_mv | AT heeyeonkim emergingtherapiesandrealworldapplicationofmetabolicdysfunctionassociatedsteatoticliverdiseasetreatment AT maryerinella emergingtherapiesandrealworldapplicationofmetabolicdysfunctionassociatedsteatoticliverdiseasetreatment |